Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Amicus Therapeutics (FOLD) Accumulated Depreciation & Amortization: 2011-2025

Historic Accumulated Depreciation & Amortization for Amicus Therapeutics (FOLD) over the last 8 years, with Sep 2025 value amounting to $1.9 million.

  • Amicus Therapeutics' Accumulated Depreciation & Amortization fell 13.64% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year decrease of 12.48%. This contributed to the annual value of $8.5 million for FY2024, which is 8.56% up from last year.
  • Amicus Therapeutics' Accumulated Depreciation & Amortization amounted to $1.9 million in Q3 2025, which was up 1.19% from $1.9 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Accumulated Depreciation & Amortization registered a high of $2.2 million during Q3 2023, and its lowest value of $1.3 million during Q1 2023.
  • For the 3-year period, Amicus Therapeutics' Accumulated Depreciation & Amortization averaged around $2.0 million, with its median value being $2.2 million (2024).
  • In the last 5 years, Amicus Therapeutics' Accumulated Depreciation & Amortization plummeted by 40.40% in 2021 and then soared by 73.25% in 2023.
  • Amicus Therapeutics' Accumulated Depreciation & Amortization (Quarterly) stood at $1.5 million in 2021, then fell by 13.64% to $1.3 million in 2022, then surged by 66.44% to $2.2 million in 2023, then decreased by 6.46% to $2.0 million in 2024, then decreased by 13.64% to $1.9 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $1.9 million for Q3 2025, versus $1.9 million for Q2 2025 and $1.8 million for Q1 2025.